The cosmetics market is one of the fast growing industries in South Korea. Notably, the popularity of cosmeceuticals is picking up, with many of the local and international cosmeceuticals companies introducing their own specialized products to attract Korean consumers, many of whom are obsessed with improving their physical appearance.
Among those home-grown cosmeceuticals brands, NeoPharm has shown marked growth since it was founded in 2000 as a spin-off venture company from Aekyung Group in Korea. The company has retained the top position in the atopic dermatitis market since its founding. NeoPharm is the technology-driven innovative company that is dedicated to improving quality of life and rendering services to humankind as a leader of skin science.
NeoPharm’s products include ATOPALM, for daily care, intensive care and special care; ZEROID, including soothing creams, soothing lotions and foaming cleansers, and Dr. MLE, including anti-aging cosmeceuticals.
Particularly, its signature atopic dermatitis skincare product “Atopalm” is a line of products formulated specifically for dry, sensitive and sun damaged skin. The unique, paraben free, patented MLE (Multi-Lamellar Emulsion) formulas, containing plant derived ingredients, mimic the structure of the natural skin lipids and provide the ultimate in revitalizing the skin’s moisture through the skin’s protective moisture barrier system.
This enables it to successfully moisturize, soothe and calm skin that is experiencing agitation from allergies, rosacea and other conditions related to dry and sensitive skin. These symptoms can be the result of the skin layers being deficient in ceramide and fatty acids. The rich, emollient, yet non-greasy technology advanced formulas, have the ability to soothe and calm while leaving the skin feeling soft, supple and looking noticeably firmer and brighter.
NeoPharm has obtained certifications such as cGMP, ISO 9001 and ISO 14001, along with local and international patents from Korea, the USA, China, Japan and Taiwan. The company plans to boost market share of Atopalm at home and abroad, particularly in the U.S. market this year.
● NeoPharm Co., Ltd.
928 Tamnip-dong, Yuseong-gu, Daejeon, Korea